Industry Deep-Dive: TPO-RAs (Romiplostim, Avatrombopag) and Syk Inhibitors (Fostamatinib) for Adult and Pediatric Patients
Global Leading Market Research Publisher QYResearch announces the release of its latest report “Thrombopoiesis Stimulating Agents – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032″. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Thrombopoiesis Stimulating Agents market, including market size, share, demand, industry development status, and forecasts for the next few years.
Core User Pain Point & Solution Direction: Hematologists and oncologists face a critical treatment challenge: patients with chronic immune thrombocytopenia (ITP) have dangerously low platelet counts (typically <30,000/μL, normal 150,000-450,000), leading to spontaneous bleeding, bruising, and risk of intracranial hemorrhage. Traditional treatments (corticosteroids, IVIg, splenectomy) have limited efficacy, significant side effects, or are invasive. Thrombopoiesis stimulating agents (TSAs) solve this through targeted platelet production enhancement. These agents stimulate megakaryocyte differentiation and platelet production in the bone marrow, including TPO receptor agonists (TPO-RAs: romiplostim, eltrombopag, avatrombopag (Doptelet), lusutrombopag (Mulpleta)) and Syk inhibitors (fostamatinib). They are also used for chemotherapy-induced thrombocytopenia (CIT) and thrombocytopenia in chronic liver disease (CLD) patients undergoing procedures.
Global Market Size & Growth Trajectory
The global market for Thrombopoiesis Stimulating Agents was estimated to be worth US4,200millionin2025andisprojectedtoreachUS4,200millionin2025andisprojectedtoreachUS 6,100 million, growing at a CAGR of 5.5% from 2026 to 2032. Market growth is driven by increasing ITP prevalence (estimated 5-10 per 100,000 adults, 3-5 per 100,000 children), expanding use in chemotherapy-induced thrombocytopenia (CIT, up to 20-30% of chemotherapy patients), and launch of oral TPO-RAs (improved convenience vs. injectable romiplostim).
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/5983851/thrombopoiesis-stimulating-agents
Market Share & Competitive Landscape
The market features a consolidated landscape with a few dominant players:
- Amgen (US) – Global leader, approximately 35% market share. Romiplostim (Nplate, injectable TPO-RA), first-in-class for ITP.
- Novartis Pharma (Switzerland) – Second-largest, approximately 15% share. Promacta/Revolade (eltrombopag, oral TPO-RA).
- Kyowa Kirin (Japan) – Approximately 8% share. Romiplostim (Japan and select markets).
- Sobi (AkaRx) – Approximately 6% share. Doptelet (avatrombopag, oral TPO-RA) for ITP and CLD.
- Rigel Pharmaceuticals (US) – Approximately 5% share. Tavalisse (fostamatinib, Syk inhibitor) for ITP.
- Shionogi, Kissei Pharmaceutical, Grifols, JW Pharmaceutical, AstraZeneca, Intas, Medison – Regional and generic players.
The top three (Amgen, Novartis, Kyowa Kirin) account for approximately 58% of global market share.
Type Segmentation by Drug
- Romiplostim (45% share) – Injectable TPO-RA (subcutaneous, weekly). First approved (2008). Strong efficacy, but requires office visits. Market share stable (5.0% CAGR).
- Eltrombopag (25% share) – Oral TPO-RA (daily). Amgen’s Promacta/Revolade. Convenient, approved for ITP and aplastic anemia. 5.5% CAGR.
- Avatrombopag (Doptelet) (12% share) – Oral TPO-RA. Fastest-growing (8% CAGR), approved for ITP and CLD thrombocytopenia. Better dosing flexibility.
- Fostamatinib (8% share) – Oral Syk inhibitor (different mechanism). For patients unresponsive to TPO-RAs. 6% CAGR.
- Mulpleta (lusutrombopag) (5% share) – Oral TPO-RA, primarily for CLD thrombocytopenia (Japan, US). 4.5% CAGR.
- Others (5% share) – Biosimilars (romiplostim) and generics (eltrombopag, entering 2026-2028).
Application Segmentation
- Adults (85% share) – Primary ITP, secondary ITP (SLE, CLL, HIV/HCV), CIT, CLD thrombocytopenia.
- Pediatric Patients (15% share) – Pediatric ITP (1+ year for romiplostim, 6+ years for eltrombopag). 6.5% CAGR (higher growth due to recent approvals).
Clinical Deep-Dive: TSA Mechanism and Indications
| Agent | Class | Route | ITP Response Rate | FDA Approvals | Key Advantages |
|---|---|---|---|---|---|
| Romiplostim | TPO-RA (peptide) | Subcutaneous weekly | 80-90% | ITP (2008), pediatric (2017) | Longest track record |
| Eltrombopag | TPO-RA (small molecule) | Oral daily | 80-85% | ITP (2008), aplastic anemia, HCV (2014) | Oral, broad approvals |
| Avatrombopag | TPO-RA | Oral daily | 80-85% | ITP (2019), CLD (2018) | No food restrictions (vs. eltrombopag) |
| Fostamatinib | Syk inhibitor | Oral BID | 40-50% (after TPO-RA failure) | ITP (2018) | Different mechanism, salvage therapy |
| Lusutrombopag | TPO-RA | Oral daily | 70-80% (CLD) | CLD (2018) | CLD-specific, short course |
Recent Clinical Breakthrough (Q1 2025) – Chemotherapy-induced thrombocytopenia (CIT) is a major unmet need (20-30% of solid tumor patients develop CIT, causing chemotherapy dose delays/reductions). Novartis announced positive Phase 3 data for eltrombopag in CIT (prevention of dose delays). If approved (expected 2026), CIT indication could expand the TPO-RA market by 30-40%.
Typical User Case (Q2 2025) – A 55-year-old chronic ITP patient (platelet count 15,000/μL, refractory to corticosteroids and IVIg) started on romiplostim (3 mcg/kg weekly). Results: Platelet count increased to 85,000/μL within 4 weeks, bruising resolved, no bleeding episodes over 12 months, and patient achieved durable response without dose escalation. Therapy continued with home administration by nurse (reduced clinic visits).
Exclusive Observation: Oral TPO-RAs Driving Market Shift
The market is shifting from injectable romiplostim to oral TPO-RAs (eltrombopag, avatrombopag) due to convenience and patient preference. Key dynamics:
| Parameter | Injectable (Romiplostim) | Oral (Eltrombopag, Avatrombopag) |
|---|---|---|
| Market share (2025) | 45% | 42% |
| Projected share (2030) | 30-35% | 50-55% |
| Patient preference | Lower (clinic visits, injections) | Higher (home dosing) |
| Adherence challenges | Clinic-based (high adherence) | Daily oral (lower adherence risk) |
| Cost per year (US) | US$ 60,000-80,000 | US$ 55,000-70,000 |
Biosimilar threat: Romiplostim biosimilars expected in 2026-2028 (Intas, others), potentially reducing price by 30-40% and shifting some share back to injectable (lower cost). However, patient preference for oral remains strong.
Industry Segmentation: Biologics and Small Molecule Manufacturing
Thrombopoiesis stimulating agents span two manufacturing categories:
| Agent Type | Manufacturing Process | Complexity | Cost of Goods | Players |
|---|---|---|---|---|
| Romiplostim (peptide) | Recombinant protein (E. coli), Fc fusion | High | US$ 2,000-5,000 per gram | Amgen (originator), biosimilars |
| Small molecule TPO-RAs (eltrombopag, avatrombopag, lusutrombopag) | Chemical synthesis (multi-step) | Medium | US$ 500-2,000 per kg | Novartis, AkaRx, Shionogi, generics |
| Fostamatinib | Chemical synthesis | Medium | US$ 500-2,000 per kg | Rigel Pharmaceuticals |
Additional Market Dynamics: The market faces challenges from (1) thrombopoietin (endogenous TPO) not developed (immunogenicity risk, has been abandoned), (2) price pressure from payers (ITP is chronic, lifetime treatment cost US$ 500,000-1,000,000), (3) generic entry for eltrombopag (2026-2028) and romiplostim biosimilars (2026-2028). However, the combination of expanding indications (CIT, CLD, pediatric), oral convenience, and unmet need in refractory ITP positions the thrombopoiesis stimulating agents market for sustained 5-7% annual growth through 2032.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
